Boothbay Fund Management’s Avalo Therapeutics AVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $56.5K | Buy |
+11,321
| New | +$56.5K | ﹤0.01% | 1151 |
|
|
2025
Q1 | – | Sell |
-163,992
| Closed | -$1.22M | – | 1226 |
|
|
2024
Q4 | $1.22M | Sell |
163,992
-100
| -0.1% | -$743 | 0.03% | 481 |
|
|
2024
Q3 | $1.56M | Buy |
+164,092
| New | +$1.56M | 0.04% | 502 |
|
|
2022
Q2 | – | Sell |
-416
| Closed | -$869K | – | 1969 |
|
|
2022
Q1 | $869K | Hold |
416
| – | – | 0.02% | 787 |
|
|
2021
Q4 | $2.04M | Sell |
416
-2
| -0.5% | -$9.8K | 0.05% | 398 |
|
|
2021
Q3 | $2.63M | Sell |
418
-11
| -3% | -$69.1K | 0.07% | 270 |
|
|
2021
Q2 | $4.04M | Hold |
429
| – | – | 0.13% | 135 |
|
|
2021
Q1 | $3.74M | Buy |
429
+27
| +7% | +$235K | 0.14% | 111 |
|
|
2020
Q4 | $3.06M | Hold |
402
| – | – | 0.11% | 133 |
|
|
2020
Q3 | $2.64M | Sell |
402
-11
| -3% | -$72.2K | 0.16% | 131 |
|
|
2020
Q2 | $3.09M | Buy |
413
+96
| +30% | +$719K | 0.21% | 91 |
|
|
2020
Q1 | $2.27M | Buy |
317
+148
| +88% | +$1.06M | 0.19% | 118 |
|
|
2019
Q4 | $2.62M | Buy |
169
+22
| +15% | +$341K | 0.23% | 95 |
|
|
2019
Q3 | $1.39M | Buy |
147
+30
| +26% | +$284K | 0.13% | 180 |
|
|
2019
Q2 | $1.84M | Hold |
117
| – | – | 0.17% | 122 |
|
|
2019
Q1 | $1.97M | Buy |
+117
| New | +$1.97M | 0.19% | 90 |
|
|
2018
Q3 | – | Sell |
-9
| Closed | -$114K | – | 663 |
|
|
2018
Q2 | $114K | Buy |
9
+1
| +13% | +$12.7K | 0.01% | 549 |
|
|
2018
Q1 | $94K | Buy |
8
+2
| +33% | +$23.5K | 0.01% | 535 |
|
|
2017
Q4 | $54K | Buy |
+6
| New | +$54K | 0.01% | 594 |
|